Brief: Bioarctic Leqembi Intravenous Infusion Approved In Japan

BioArctic AB

25/09/2023 06:06

Sept 25 (Reuters) - BioArctic AB  BIOAb.ST :
    * LEQEMBI INTRAVENOUS INFUSION APPROVED FOR TREATMENT OF ALZHEIMER'S DISEASE IN JAPAN
    * REGULATORY APPROVAL IN JAPAN ANNOUNCED TODAY, ENTITLES BIOARCTIC TO A MILESTONE OF EUR 17
M
    * LEQEMBI INTRAVENOUS INFUSION (200 MG, 500MG, LECANEMAB) HAS BEEN APPROVED IN JAPAN AS A
TREATMENT FOR SLOWING PROGRESSION OF MILD COGNITIVE IMPAIRMENT (MCI) AND MILD DEMENTIA DUE TO
ALZHEIMER'S DISEASE (AD)

Source text for Eikon:  ID:nWkr789D73 
Further company coverage:  BIOAb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))